231 related articles for article (PubMed ID: 28299826)
1. International regulatory requirements for genotoxicity testing for pharmaceuticals used in human medicine, and their impurities and metabolites.
Galloway SM
Environ Mol Mutagen; 2017 Jun; 58(5):296-324. PubMed ID: 28299826
[TBL] [Abstract][Full Text] [Related]
2. International Conference on Harmonisation; guidance on S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals intended for Human Use; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2012 Jun; 77(110):33748-9. PubMed ID: 22675782
[TBL] [Abstract][Full Text] [Related]
3. Genotoxicity testing: current practices and strategies used by the pharmaceutical industry.
Purves D; Harvey C; Tweats D; Lumley CE
Mutagenesis; 1995 Jul; 10(4):297-312. PubMed ID: 7476265
[TBL] [Abstract][Full Text] [Related]
4. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
[TBL] [Abstract][Full Text] [Related]
5. How to assess the mutagenic potential of cosmetic products without animal tests?
Speit G
Mutat Res; 2009 Aug; 678(2):108-12. PubMed ID: 19379833
[TBL] [Abstract][Full Text] [Related]
6. Regulatory requirements for genotoxicity assessment of plant protection product active ingredients, impurities, and metabolites.
Booth ED; Rawlinson PJ; Maria Fagundes P; Leiner KA
Environ Mol Mutagen; 2017 Jun; 58(5):325-344. PubMed ID: 28329407
[TBL] [Abstract][Full Text] [Related]
7. Genetic toxicity assessment: employing the best science for human safety evaluation part IV: a strategy in genotoxicity testing in drug development: some examples.
Lorge E; Gervais V; Becourt-Lhote N; Maisonneuve C; Delongeas JL; Claude N
Toxicol Sci; 2007 Jul; 98(1):39-42. PubMed ID: 17369197
[TBL] [Abstract][Full Text] [Related]
8. In silico prediction of genotoxicity.
Wichard JD
Food Chem Toxicol; 2017 Aug; 106(Pt B):595-599. PubMed ID: 27979779
[TBL] [Abstract][Full Text] [Related]
9. Establishing best practise in the application of expert review of mutagenicity under ICH M7.
Barber C; Amberg A; Custer L; Dobo KL; Glowienke S; Van Gompel J; Gutsell S; Harvey J; Honma M; Kenyon MO; Kruhlak N; Muster W; Stavitskaya L; Teasdale A; Vessey J; Wichard J
Regul Toxicol Pharmacol; 2015 Oct; 73(1):367-77. PubMed ID: 26248005
[TBL] [Abstract][Full Text] [Related]
10. ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact.
Müller L; Kikuchi Y; Probst G; Schechtman L; Shimada H; Sofuni T; Tweats D
Mutat Res; 1999 May; 436(3):195-225. PubMed ID: 10354523
[TBL] [Abstract][Full Text] [Related]
11. Transitioning to composite bacterial mutagenicity models in ICH M7 (Q)SAR analyses.
Landry C; Kim MT; Kruhlak NL; Cross KP; Saiakhov R; Chakravarti S; Stavitskaya L
Regul Toxicol Pharmacol; 2019 Dec; 109():104488. PubMed ID: 31586682
[TBL] [Abstract][Full Text] [Related]
12. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
[TBL] [Abstract][Full Text] [Related]
13. A consortium-driven framework to guide the implementation of ICH M7 Option 4 control strategies.
Barber C; Antonucci V; Baumann JC; Brown R; Covey-Crump E; Elder D; Elliott E; Fennell JW; Gallou F; Ide ND; Jordine G; Kallemeyn JM; Lauwers D; Looker AR; Lovelle LE; McLaughlin M; Molzahn R; Ott M; Schils D; Oestrich RS; Stevenson N; Talavera P; Teasdale A; Urquhart MW; Varie DL; Welch D
Regul Toxicol Pharmacol; 2017 Nov; 90():22-28. PubMed ID: 28822875
[TBL] [Abstract][Full Text] [Related]
14. Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses.
Amberg A; Beilke L; Bercu J; Bower D; Brigo A; Cross KP; Custer L; Dobo K; Dowdy E; Ford KA; Glowienke S; Van Gompel J; Harvey J; Hasselgren C; Honma M; Jolly R; Kemper R; Kenyon M; Kruhlak N; Leavitt P; Miller S; Muster W; Nicolette J; Plaper A; Powley M; Quigley DP; Reddy MV; Spirkl HP; Stavitskaya L; Teasdale A; Weiner S; Welch DS; White A; Wichard J; Myatt GJ
Regul Toxicol Pharmacol; 2016 Jun; 77():13-24. PubMed ID: 26877192
[TBL] [Abstract][Full Text] [Related]
15. Considerations on photochemical genotoxicity. II: report of the 2009 International Workshop on Genotoxicity Testing Working Group.
Lynch AM; Guzzie PJ; Bauer D; Gocke E; Itoh S; Jacobs A; Krul CA; Schepky A; Tanaka N; Kasper P
Mutat Res; 2011 Aug; 723(2):91-100. PubMed ID: 21296679
[TBL] [Abstract][Full Text] [Related]
16. Testing strategies in mutagenicity and genetic toxicology: an appraisal of the guidelines of the European Scientific Committee for Cosmetics and Non-Food Products for the evaluation of hair dyes.
Kirkland DJ; Henderson L; Marzin D; Müller L; Parry JM; Speit G; Tweats DJ; Williams GM
Mutat Res; 2005 Dec; 588(2):88-105. PubMed ID: 16326131
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for the evaluation of complex genetic toxicity data sets when assessing carcinogenic risks to humans.
Eastmond DA
Environ Mol Mutagen; 2017 Jun; 58(5):380-385. PubMed ID: 28266084
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of in-house and off-the-shelf in silico models: implications on guidance for mutagenicity assessment.
Jolly R; Ahmed KB; Zwickl C; Watson I; Gombar V
Regul Toxicol Pharmacol; 2015 Apr; 71(3):388-97. PubMed ID: 25656493
[TBL] [Abstract][Full Text] [Related]
19. Role of in silico genotoxicity tools in the regulatory assessment of pharmaceutical impurities.
Fioravanzo E; Bassan A; Pavan M; Mostrag-Szlichtyng A; Worth AP
SAR QSAR Environ Res; 2012; 23(3-4):257-77. PubMed ID: 22369620
[TBL] [Abstract][Full Text] [Related]
20. Genotoxicity assessment of peptide/protein-related biotherapeutics: points to consider before testing.
Thybaud V; Kasper P; Sobol Z; Elhajouji A; Fellows M; Guerard M; Lynch AM; Sutter A; Tanir JY
Mutagenesis; 2016 Jul; 31(4):375-84. PubMed ID: 27000792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
